A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors

NCT07698587 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: BM230 & PD-1 inhibitor
DRUG: BM230 & PD-1 inhibitor

Sponsor

Suzhou Biomissile Pharmaceuticals Co., Ltd.